Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection

American Journal of Respiratory and Critical Care Medicine

Volumn 154, Issue 4 I, 1996, Pages 1034-1038

  Chaisson, Richard E ^a   Clermont, H Camil ^b   Holt, Elizabeth A ^b   Cantave, Mireille ^b   Johnson, Michael P ^b   Atkinson, Joan ^b   Davis, Homer ^b   Boulos, Reginald ^b   Quinn, Thomas C ^b   Halsey, Neal A ^b   Desormeaux, Julio ^b   Joseph, Henri ^b   Buteau, Josianne ^b   LaMothe, Franz ^b   Elie, Robert ^b   Charache, Patricia ^b   Siddiqi, Salman ^b   Eaton, Abigail ^b   Clements, Audrey ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; DEVELOPING COUNTRY; FEMALE; HAITI; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SERODIAGNOSIS; SURVIVAL RATE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 10244242548     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.154.4.8887603     Document Type: Article

References (27)

1. Harries, A. D. 1990. Tuberculosis and human immunodeficiency virus in developing countries. Lancet 335:387-390.
2. Colebunders, R. L., R. W. Ryder, N. Nzilambi, K. Dikilu, T.-C. Willame, M. Kaboto, N. Bagala, J. Jeugmans, K. Muepu, H. L. Francis, J. M. Mann, T. C. Quinn, and P. Piot. 1989. HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am. Rev. Respir. Dis. 139: 1082-1085.
3. Raviglione, M. C., J. P. Narain, and A. Kochi. 1992. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull. W.H.O. 70:515-526.
4. DeCock, K. M., B. Soro, I. M. Coulibaly, and S. B. Lucas. 1992. Tuberculosis and HIV infection in sub-Saharan Africa. J.A.M.A. 268: 1581-1587.
5. Small, P. M., G. F. Schecter, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. 1991. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 324:289-294.
6. Jones, B. E., M. Otaya, D. Atoniskis, S. Sian, F. Wang, A. Mercado, P. T. Davidson, and P. F. Barnes. 1994. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am. J. Respir. Crit. Care Med. 150:1499-1502.
7. Advisory Committee for the Elimination of Tuberculosis. 1989. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). M.M.W.R. 38:236-250.
8. Barnes, P. F., A. H. Bloch, P. T. Davidson, and D. H. Snider. 1991. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 324:1644-1650.
9. Alwood, K., J. C. Keruly, K. Moore-Rice, D. L., Stanton, P. Chaulk, and R. E. Chaisson. 1994. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV infected patients. AIDS 8:1103-1108.
10. Perriens, J. H., R. L. Colebunders, C. Karahunga, J. Willame, J. Jeugmans, M. Kaboto, Y. Mukadi, P. Pauwels, P. W. Ryder, J. Prignot, and P. Piot. 1991. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am. Rev. Respir. Dis. 144:750-755.
11. Nunn, P., D. Kibuga, S. Gathua, R. Brindle, A. Imalingal, K. Wassunna, S. Lucas, C. Gilks, M. Omwega, J. Were, and K. McAdam. 1991. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 337:627-630.
12. Hawken, M., P. Nunn, S. Gathua, R. Brindle, P. Godfrey-Taussett, W. Githui, J. Adhiambo, B. Batchelor, C. Gilks, J. Morris, and K. McAdam. 1993. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 342: 332-337.
13. Okwere, A., C. Whalen, F. Byekwaso, M. Vjecha, J. Johnson, R. Huoebner, R. Mugerwa, J. Ellner and the Makerene University-Case Western Reserve University Research Collaboration. 1994. Randomized trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 344: 1323-1328.
14. Ackah, A. N., D. Coulibaly, H. Digbeu, K. Diallo, K. M. Vetter, I.-M. Coulibaly, A. Greenberg, and K. M. DeCock. 1995. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'lvoire. Lancet 345:607-610.
15. Kent, P. T., and G. D. Kubica. 1985. Public Health Mycobacteriology: A Guide for the Level III Laboratory. Centers for Disease Control, Atlanta.
16. Perriens, J. H., M. E. St. Louis, Y. B. Mukadi, C. Brown, J. Prignot, F. Pouthier, F. Partaels, J.-C. Willame, J. Mandala, M. Kaboto, R. W. Ryder, and G. Roseigno. 1995. Pulmonary tuberculosis in HIV-infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months. N. Engl. J. Med. 332:779-784.
17. Johnson, M. P., J. S. Coberly, H. C. Clermont, R. E. Chaisson, H. I. Davis, P. Losikoff, A. J. Ruff, A. Boulos, and N. A. Halsey. 1992. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J. Infect. Dis. 166:194-198.
18. Small, P. M., R. W. Shafer, P. C. Hopewell, S. P. Singh, M. J. Murphy, E. Desmond, M. F. Sierra, and G. K. Schoolnik. 1993. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 328: 1137-1144.
19. Hong Kong Chest Service/British Medical Research Council. 1991. Controlled Trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am. Rev. Respir. Dis. 143: 700-706.
20. Singapore Tuberculosis Service/British Medical Research Council. 1991. Assessment of a daily combined preparation of isoniazid, rifampin and pyrazinamide in a controlled trial of three 6-month regimens for smear positive pulmonary tuberculosis. Am. Rev. Respir. Dis. 143:707-712.
21. Hong Kong Chest Service/British Medical Research Council. 1987. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am. Rev. Respir. Dis. 136:1339-1342.
22. Lucas, S. B., K. M. DeCock, A. Hounnou, C. Peacock, M. Diomande, M. Hondé, A. Beaumel, I. Kestens, and A. Kadio. 1994. Contribution of tuberculosis to slim disease in Africa. B.M.J. 308:1531-1533.
23. Lucas, S. B., A. Hounnou, C. Peacock, A. Beaumel, G. Djoand, J.-M. N'Gbichi, K. Yeboue, M. Hondé, M. Diomande, C. Giardano, R. Doorly, K. Brattlegaard, L. Kestens, R. Smithwick, A. Kadio, N. Ezani, A. Yapi, and K. M. DeCock. 1993. The mortality and pathology of HIV infection in a west African city. AIDS 7:1569-1579.
24. Weiss, S. E., P. C. Slocum, F. X. Blais, B. King, M. Nunn, G. B. Matney, E. Gomez, and B. H. Foresman. 1994. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med. 330:1179-1184.
25. Chaulk, C. P., K. Moore-Rice, R. T. Rizzo, and R. E. Chaisson. 1995. Eleven years of community based directly observed therapy for tuberculosis. J.A.M.A. 274:945-951.
26. Brudney, K., and J. Dobkin. 1991. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am. Rev. Respir. Dis. 144:745-749.
27. Farmer, P., S. Robin, S. I., Ramilus, and J. Y. Kim. 1991. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. Semin. Respir. Infect. 8:254-260.